نتایج جستجو برای: blinatumomab
تعداد نتایج: 330 فیلتر نتایج به سال:
Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Despite advances in current management, patients continue to have poo...
The CD20-directed monoclonal antibody rituximab established a new era in lymphoma therapy. Since then other epitopes on the lymphoma surface have been identified as potential targets for monoclonal antibodies (mAb). While most mAbs eliminate lymphoma cells mainly by antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or direct cell death, others counter mechanisms utiliz...
T-cell immunotherapies are promising options in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We investigated the effect of co-signaling molecules on T-cell attack against leukemia mediated by CD19/CD3-bispecific T-cell engager. Primary CD19+ ALL blasts (n≥10) and physiologic CD19+CD10+ bone marrow precursors were screened for 20 co-signaling molecules. PD-L1, PD-1, LAG-3,...
CD19-directed treatment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry (MFC) application for minimal/measurable residual disease (MRD) assessment BCP-ALL is based on compartment study, CD19 loss could hamper MFC-MRD monitoring after blinatumomab or chimeric antigen receptor T-cell (CAR-T) the...
Lineage switch is a rare phenomenon in which acute leukemia transforms from lymphoid to myeloid lineage, or vice versa. It is typically seen following therapy or at the time of relapse. Among the chromosomal aberrations associated with lineage switch, the t(4;11)(q21;q23) rearrangement with KMT2A/AFF1 fusion protein (formerly, MLL/AFF1 or MLL/AF4) is the most common. In general, lineage switch ...
1Amgen Research (Munich) GmbH, Munich, Germany; 2Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; 3Medizinische Klinik II, Johann Wolfgang Goethe Universitätsklinikum, Frankfurt am Main, Germany; 4II Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; 5Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Ge...
Blinatumomab: A Promising New Drug in the Therapeutic Armamentarium for Acute Lymphoblastic Leukemia
The anti CD19/CD3-bispecific T cell–engager monoclonal antibody blinatumomab is an effective drug with an acceptable toxic profile for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This high efficacy has also been observed in patients with minimal residual disease. These favorable results have led to the investigation of the activity of thi...
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager ...
Background: Overexpression of the c-MYC oncogene (hereafter MYC) was implicated to suppress tumor immune surveillance and shown associate with poor clinical outcome in several malignancies. Here, we investigated its impact on anti-tumor effect antibody T-cell based immunotherapies diffuse large B-cell lymphoma (DLBCL), Burkitt (BL) multiple myeloma (MM). Methods: Using CRISPR-Cas9 gene editing ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید